Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 3/20 | 0.51 |
| ▸ | CTSG | P08311 | 2/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.49 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 2/20 | 0.46 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.46 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.46 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.46 |
| ▸ | F12 | P00748 | 2/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | BAD | Q92934 | 1/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.45 |
| ▸ | OXTR | P30559 | 1/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.45 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.45 |
| ▸ | KRAS | P01116 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16349623 | 0.95 | PLAU (0.46) | PLAUCTSGKLKB1TSLPEPHA2 | |
| SCHEMBL16349705 | 0.89 | SSTR2 (0.47) | PLAUCTSGKLKB1KLK7SSTR1 | |
| SCHEMBL13113566 | 0.89 | SSTR2 (0.50) | PLAUCTSGKLKB1KLK7SSTR1 | |
| SCHEMBL13287941 | 0.88 | SSTR2 (0.50) | PLAUCTSGKLKB1KLK7SSTR1 | |
| SCHEMBL12082795 | 0.87 | IL23R (0.52) | PLAUCTSGTSLPEPHA2SSTR1 | |
| SCHEMBL13113570 | 0.86 | SSTR2 (0.44) | PLAUKLKB1TSLPEPHA2KLK7 | |
| SCHEMBL12085211 | 0.84 | ALB (0.44) | PLAUCTSGKLKB1TSLPEPHA2 | |
| SCHEMBL13113564 | 0.83 | KLK7 (0.44) | PLAUKLKB1TSLPEPHA2KLK7 | |
| SCHEMBL13287918 | 0.81 | ALB (0.47) | PLAUCTSGKLKB1TSLPEPHA2 | |
| SCHEMBL13319649 | 0.81 | CTSG (0.69) | PLAUCTSGKLKB1TSLP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258101-B2 | Peptide-based compounds | GE HEALTHCARE AS (NO) | 2012-09-04 | — | — | US | disclosed |
| US-20100256330-A1 | Peptide-based compounds | CUTHBERTSON ALAN | 2010-10-07 | — | — | US | disclosed |
| US-20100256330-A1 | Peptide-based compounds | CUTHBERTSON ALAN | 2010-10-07 | — | — | US | disclosed |
| US-7737252-B2 | Peptide-based compounds | GE HEALTHCARE AS (NO) | 2010-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256330-A1 | Peptide-based compounds | VCAM1, FLT4, KDR | PLAU 1048/4885CTSG 601/4885KLKB1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.